Jack Allen
Stock Analyst at Baird
(1.54)
# 3,314
Out of 4,944 analysts
42
Total ratings
40.62%
Success rate
-7.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Maintains: Neutral | $0.25 → $1 | $2.02 | -50.50% | 4 | Jun 27, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.13 | +253.98% | 2 | May 14, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $12 → $9 | $1.04 | +765.38% | 3 | May 14, 2025 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.29 | +241.30% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $17.50 | +128.57% | 2 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $70.90 | +49.51% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $11.00 | +63.64% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $26.97 | +567.41% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $1.73 | +362.43% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $57.33 | -9.30% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $33.00 | +154.55% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $3.03 | +164.03% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.03 | +385.44% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.79 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.65 | +146.58% | 1 | Oct 7, 2021 |
Vor Biopharma
Jun 27, 2025
Maintains: Neutral
Price Target: $0.25 → $1
Current: $2.02
Upside: -50.50%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.13
Upside: +253.98%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $12 → $9
Current: $1.04
Upside: +765.38%
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.29
Upside: +241.30%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $17.50
Upside: +128.57%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $70.90
Upside: +49.51%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $11.00
Upside: +63.64%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $26.97
Upside: +567.41%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $1.73
Upside: +362.43%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $57.33
Upside: -9.30%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $33.00
Upside: +154.55%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $3.03
Upside: +164.03%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.03
Upside: +385.44%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.79
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.65
Upside: +146.58%